Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib

Pinter, Matthias, Hucke, Florian, Graziadei, Ivo, Vogel, Wolfgang, Maieron, Andreas, Königsberg, Robert, Stauber, Rudolf, Grünberger, Birgit, Müller, Christian, Kölblinger, Claus, Peck-Radosavljevic, Markus, Sieghart, Wolfgang·2012·Radiology

Abstract

PURPOSE: To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The retrospective analysis of the data was approved by the institutional review board; the requirement to obtain informed consent was waived. Three hundred seventy-two patients with HCC were treated between January 1999 and December 2009. Patients with advanced HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging classification (Child-Pugh class A or B, Eastern Cooperative Oncology Group performance status of 1-2, and/or macrovascular invasion or extrahepatic metastasis) were included in the study (n = 97). Thirty-four patients underwent conventional TACE with doxorubicin plus lipiodol or TACE with drug-eluting beads; 63 patients were treated with sorafenib. RESULTS: The median duration of sorafenib treatment was 4.6 months (95% confidence interval [CI]: 3.2, 6.0 months). The median number of TACE sessions per patient was 3 ± 2. Side effects of TACE and sorafenib were comparable to those reported in the literature. The median time to progression was similar between the two treatment groups (P = .737). The median overall survival was 9.2 months (95% CI: 6.1, 12.3 months) for patients treated with TACE and 7.4 months (95% CI: 5.6, 9.2 months) for those treated with sorafenib (P = .377). Only Child-Pugh class was associated with a better overall survival at uni- and multivariate analysis. CONCLUSION: TACE achieved a promising outcome in select patients with advanced HCC (BCLC stage C).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1148/radiol.12111550

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 197

Metadata

Authors
Pinter, M., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Stauber, R., Grünberger, B., Müller, C., Kölblinger, C., Peck-Radosavljevic, M., & Sieghart, W.
Venue
Radiology
Published
2012-05
Volume
263
Issue
2
Pages
590-599
ISSN
  • 0033-8419 (ISSN-L)
  • 1527-1315
OpenAlex
W2098618036
Cited by
197
References
2
FWCI
11.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. https://app.cochat.ai/papers/10.1148/radiol.12111550
The paper
Pinter, M., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Stauber, R., Grünberger, B., Müller, C., Kölblinger, C., Peck-Radosavljevic, M., & Sieghart, W. (2012). Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology. https://doi.org/10.1148/radiol.12111550

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.